SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy
- PMID: 32642005
- PMCID: PMC7330865
- DOI: 10.7150/thno.48076
SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy
Abstract
The COVID-19 pandemic is an emerging threat to global public health. While our current understanding of COVID-19 pathogenesis is limited, a better understanding will help us develop efficacious treatment and prevention strategies for COVID-19. One potential therapeutic target is angiotensin converting enzyme 2 (ACE2). ACE2 primarily catalyzes the conversion of angiotensin I (Ang I) to a nonapeptide angiotensin or the conversion of angiotensin II (Ang II) to angiotensin 1-7 (Ang 1-7) and has direct effects on cardiac function and multiple organs via counter-regulation of the renin-angiotensin system (RAS). Significant to COVID-19, ACE2 is postulated to serve as a major entry receptor for SARS-CoV-2 in human cells, as it does for SARS-CoV. Many infected individuals develop COVID-19 with fever, cough, and shortness of breath that can progress to pneumonia. Disease progression promotes the activation of immune cells, platelets, and coagulation pathways that can lead to multiple organ failure and death. ACE2 is expressed by epithelial cells of the lungs at high level, a major target of the disease, as seen in post-mortem lung tissue of patients who died with COVID-19, which reveals diffuse alveolar damage with cellular fibromyxoid exudates bilaterally. Comparatively, ACE2 is expressed at low level by vascular endothelial cells of the heart and kidney but may also be targeted by the virus in severe COVID-19 cases. Interestingly, SARS-CoV-2 infection downregulates ACE2 expression, which may also play a critical pathogenic role in COVID-19. Importantly, targeting ACE2/Ang 1-7 axis and blocking ACE2 interaction with the S protein of SARS-CoV-2 to curtail SARS-CoV-2 infection are becoming very attractive therapeutics potential for treatment and prevention of COVID-19. Here, we will discuss the following subtopics: 1) ACE2 as a receptor of SARS-CoV-2; 2) clinical and pathological features of COVID-19; 3) role of ACE2 in the infection and pathogenesis of SARS; 4) potential pathogenic role of ACE2 in COVID-19; 5) animal models for pathological studies and therapeutics; and 6) therapeutics development for COVID-19.
Keywords: ACE2; COVID-19; and animal model; pathogenesis; spike protein.
© The author(s).
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
Figures
Similar articles
-
Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting.Eur J Pharmacol. 2020 Oct 5;884:173455. doi: 10.1016/j.ejphar.2020.173455. Epub 2020 Jul 31. Eur J Pharmacol. 2020. PMID: 32745604 Free PMC article. Review.
-
A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.Rev Med Virol. 2020 Sep;30(5):e2119. doi: 10.1002/rmv.2119. Epub 2020 Jun 25. Rev Med Virol. 2020. PMID: 32584474 Free PMC article. Review.
-
The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):317-325. doi: 10.1093/ehjcvp/pvaa053. Eur Heart J Cardiovasc Pharmacother. 2020. PMID: 32464637 Free PMC article. Review.
-
Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).J Pathol. 2020 Jul;251(3):228-248. doi: 10.1002/path.5471. Epub 2020 Jun 10. J Pathol. 2020. PMID: 32418199 Free PMC article. Review.
-
Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.J Med Virol. 2020 Jul;92(7):726-730. doi: 10.1002/jmv.25785. Epub 2020 Apr 5. J Med Virol. 2020. PMID: 32221983 Free PMC article. Review.
Cited by
-
COVID-19 Variants and Vaccine Development.Viruses. 2024 May 10;16(5):757. doi: 10.3390/v16050757. Viruses. 2024. PMID: 38793638 Free PMC article. Review.
-
Oral symptoms potentially associated with mild-to-moderate COVID-19 in tobacco users.Tob Induc Dis. 2024 May 13;22. doi: 10.18332/tid/186531. eCollection 2024. Tob Induc Dis. 2024. PMID: 38742218 Free PMC article.
-
RNA m5C methylation modification: a potential therapeutic target for SARS-CoV-2-associated myocarditis.Front Immunol. 2024 Apr 23;15:1380697. doi: 10.3389/fimmu.2024.1380697. eCollection 2024. Front Immunol. 2024. PMID: 38715608 Free PMC article. Review.
-
Natural Killer Cells Do Not Attenuate a Mouse-Adapted SARS-CoV-2-Induced Disease in Rag2-/- Mice.Viruses. 2024 Apr 15;16(4):611. doi: 10.3390/v16040611. Viruses. 2024. PMID: 38675952 Free PMC article.
-
Understanding COVID-19-associated endothelial dysfunction: role of PIEZO1 as a potential therapeutic target.Front Immunol. 2024 Feb 29;15:1281263. doi: 10.3389/fimmu.2024.1281263. eCollection 2024. Front Immunol. 2024. PMID: 38487535 Free PMC article. Review.
References
-
- Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS letters. 2002;532:107–10. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous